Format

Send to

Choose Destination
PLoS One. 2016 Aug 10;11(8):e0159672. doi: 10.1371/journal.pone.0159672. eCollection 2016.

The Use of Antihypertensive Medication and the Risk of Breast Cancer in a Case-Control Study in a Spanish Population: The MCC-Spain Study.

Author information

1
CIBER Epidemiologia y Salud Pública (CIBERESP), Madrid, Spain.
2
University of Cantabria-IDIVAL, Santander, Spain.
3
Cancer and Environmental Epidemiology Unit, National Center for Epidemiology, Carlos III Institute of Health, Madrid, Spain.
4
Cancer Epidemiology Research Group, Oncology and Hematology Area, IIS Puerta de Hierro (IDIPHIM), Madrid, Spain.
5
Servei d'Oncologia Mèdica, Hospital del Mar, Barcelona, Spain.
6
Cancer Research Program IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain.
7
Universitat Autònoma de Barcelona, Barcelona, Spain.
8
Cancer Prevention and Control Program, Catalan Institute of Oncology-IDIBELL, and University of Barcelona, Barcelona, Spain.
9
Public Health Division of Gipuzkoa, Biodonostia Research Institute, Guipuzkoa, Spain.
10
Área de Medicina Preventiva y Salud Pública, Departamento de Ciencias Biomédicas, Universidad de León, León, España.
11
Grupo de Investigación en Interacciones Gen-Ambiente y Salud (GIIGAS), Universidad de León, León, España.
12
Navarra Public Health Institute, Pamplona, Spain.
13
Navarra Institute for Health Research (IdiSNA) Pamplona, Pamplona, Spain.
14
IUOPA, Universidad de Oviedo, Oviedo, Spain.
15
Hospital Juan Ramon Jimenez, Andalusian Health Service, Huelva, España.
16
Research Center for Health and the Environment (CYSMA), Universidad de Huelva, Huelva, España.
17
Area de Cáncer y Salud Pública, Fundación FISABIO- Salud Pública, Valencia, Spain.
18
Epidemiology Unit and Girona Cancer Registry, Oncology Coordination Plan, Department of Health, Autonomous Government of Catalonia and Descriptive Epidemiology, Genetics and Cancer Prevention Group [Girona Biomedical Research Institute (IdIBGi)], Catalan Institute of Oncology, Girona, Spain.
19
Translational Genomics and Targeted Therapeutics in Solid Tumors (IDIBAPS), Barcelona, Spain.
20
Onkologikoa- Oncology Institute Gipuzkoa, Guipuzkoa, Spain.
21
Pharmacy Service, Complex assistive university Leon, Leon, Spain.
22
Navarra Institute for Health Research (IdiSNA), Pamplona, Spain.
23
Centre for Research in Environmental Epidemiology (CREAL), Barcelona, Spain.
24
Universitat Pompeu Fabra (UPF), Barcelona, Spain.
25
IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain.

Abstract

INTRODUCTION:

The evidence on the relationship between breast cancer and different types of antihypertensive drugs taken for at least 5 years is limited and inconsistent. Furthermore, the debate has recently been fueled again with new data reporting an increased risk of breast cancer among women with a long history of use of antihypertensive drugs compared with nonusers.

METHODS:

In this case-control study, we report the antihypertensive drugs-breast cancer relationship in 1,736 breast cancer cases and 1,895 healthy controls; results are reported stratifying by the women's characteristics (i.e., menopausal status or body mass index category) tumor characteristics and length of use of antihypertensive drugs.

RESULTS:

The relationship among breast cancer and use of calcium channel blockers (CCB) for 5 or more years had odds ratio (OR) = 1.77 (95% CI, 0.99 to 3.17). Stratifying by BMI, the OR increased significantly in the group with BMI ≥ 25 (OR 2.54, 95% CI, 1.24 to 5.22). CCBs were even more strongly associated with more aggressive tumors, (OR for invasive tumors = 1.96, 95% CI = 1.09 to 3.53; OR for non ductal cancers = 3.97, 95% CI = 1.73 to 9.05; OR for Erbb2+ cancer = 2.97, 95% CI: 1.20 to 7.32). On the other hand, premenopausal women were the only group in which angiotensin II receptor blockers may be associated with breast cancer (OR = 4.27, 95% CI = 1.32 to 13.84) but this could not be identified with any type or stage. Use of angiotensin-converting-enzyme inhibitors, beta blockers and diuretics were not associated with risk.

CONCLUSIONS:

In this large population-based study we found that long term use of calcium channel blockers is associated with some subtypes of breast cancer (and with breast cancer in overweight women).

PMID:
27508297
PMCID:
PMC4979888
DOI:
10.1371/journal.pone.0159672
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Public Library of Science Icon for PubMed Central
Loading ...
Support Center